These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 22714051)

  • 1. Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein.
    Sumbria RK; Boado RJ; Pardridge WM
    J Cereb Blood Flow Metab; 2012 Oct; 32(10):1933-8. PubMed ID: 22714051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.
    Zhou QH; Sumbria R; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    J Pharmacol Exp Ther; 2011 Nov; 339(2):618-23. PubMed ID: 21831964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
    Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
    Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins.
    Sumbria RK; Boado RJ; Pardridge WM
    Brain Res; 2013 Apr; 1507():91-6. PubMed ID: 23428543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain-penetrating tumor necrosis factor decoy receptor in the mouse.
    Zhou QH; Boado RJ; Hui EK; Lu JZ; Pardridge WM
    Drug Metab Dispos; 2011 Jan; 39(1):71-6. PubMed ID: 20884844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.
    Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Brain Res; 2011 Jan; 1369():203-7. PubMed ID: 21047502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice.
    Sumbria RK; Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Mol Pharm; 2013 Apr; 10(4):1425-31. PubMed ID: 23410508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.
    Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
    J Biotechnol; 2010 Mar; 146(1-2):84-91. PubMed ID: 20100527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic TNFα-inhibitors that cross the human blood-brain barrier.
    Pardridge WM
    Bioeng Bugs; 2010; 1(4):231-4. PubMed ID: 21327054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy.
    Ou W; Yang J; Simanauskaite J; Choi M; Castellanos DM; Chang R; Sun J; Jagadeesan N; Parfitt KD; Cribbs DH; Sumbria RK
    J Neuroinflammation; 2021 Dec; 18(1):312. PubMed ID: 34972522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
    Pardridge WM; Boado RJ
    Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.
    Hui EK; Boado RJ; Pardridge WM
    Mol Pharm; 2009; 6(5):1536-43. PubMed ID: 19624167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse.
    Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Drug Metab Dispos; 2010 Apr; 38(4):566-72. PubMed ID: 20075191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.
    Boado RJ; Zhou QH; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2010 Feb; 7(1):237-44. PubMed ID: 19921848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.
    Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Brain Res; 2011 Mar; 1382():315-20. PubMed ID: 21276430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
    Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
    Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
    Pardridge WM
    Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
    Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.
    Zhou QH; Fu A; Boado RJ; Hui EK; Lu JZ; Pardridge WM
    Mol Pharm; 2011 Feb; 8(1):280-5. PubMed ID: 21141969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.